Q-omics provides the consensus-scored MYL12BP2 profile across patient tissues and cancer cell-line models. MYL12BP2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MYL12BP2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, MYL12BP2 RNA expression shows 9,616 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, COAD, and TGCT as cancer lineages where MYL12BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYL12BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYL12BP2 survival associations across molecular data types. MYL12BP2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYL12BP2 RNA expression–survival associations across cancer types. High MYL12BP2 expression shows unfavorable associations in LGG and KIRC, but favorable associations in SKCM, UCEC, LUSC and OV. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MYL12BP2 RNA expression.
This table summarizes MYL12BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MYL12BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYL12BP2 shows lower tumor expression in THCA and KIRP and higher tumor expression in COAD, LIHC, LUSC and BRCA. The COAD box plot shows higher MYL12BP2 RNA expression in tumor versus normal tissue (log2 FC = +0.898, t-test p < 0.001).
This table shows molecular features associated with MYL12BP2 in patient tissues and cancer cell lines. In patient samples, MYL12BP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
